Navigation Links
Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session

630. Individual patients treated with CB7630 also experienced improvement in pain and a reduction in opioid use. Circulating tumor cells (CTC) were detected in 14 of 19 patients and changes in CTC counts were shown to correlate with changes in PSA.

Dr. Arie S. Belldegrun, M.D., FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology, said, "The data from both trials of CB7630 presented at AACR continues to support the potential role of the drug in the treatment of CRPC. Interestingly, CB7630 showed strong evidence of antitumor activity in patients who were both chemotherapy naive and chemotherapy refractory, both of which represent significant unmet medical needs in prostate cancer. We continue to have strong confidence in CB7630's potential in both of these patient populations." Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "We are pleased to be able to present data from both of these CB7630 trials at AACR. We look forward to continuing to provide updates on these ongoing trials at future cancer conferences and greatly look forward to the continued development of CB7630 in both the second line hormone therapy and second line chemotherapy settings."

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

This press release contains f
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
3. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
(Date:12/1/2008)...ll/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ...world,s leading medical journals, results of clini...imental compound tasimelteon (VEC-162). The publi...in agonist tasimelteon (VEC-162) for transient ins...olled multicentre trials." Results are reported fr...
(Date:12/1/2008)...wo-way switch that, if turned off, causes lymphati...y lose their identity and become more like blood e... Scientists at St. Jud...t a certain differentiated cell type is so ready t...t expression of a gene called Prox1 to dissuade ...
(Date:12/1/2008)...GeoVax Labs, Inc.,(OTC Bulletin Board: GOVX), an ...man vaccines for diseases caused by HIV-1 (Human I...s, announced today that the launch of its Phase 2a...ites across North and South America.,These trials...Institutes of,Health (NIH), and the HIV Vaccine T...
(Date:11/28/2008)...l/ -- Eli Lilly and Company,(NYSE: LLY ) has wi...A) from,the U.S. Food and Drug Administration (FD...ement of chronic pain. Lilly plans to resubmit the...ta from a recently completed positive study,in ch...e decision does not affect duloxetine,s FDA-approv...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 1Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 2Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 3Forterus Inc Announces Stock Buyback 29598 1Forterus Inc Announces Stock Buyback 29598 2The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 1The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 2The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 3The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 4Innovative Wellness Project Launched in Four Maine School Districts 29592 1Innovative Wellness Project Launched in Four Maine School Districts 29592 2
(Date:12/2/2008)... 2 The Healthcare group at,Frost ... is pleased to announce that,it will be hosting a...,sub-Saharan Africa on Friday 12 December at 16h0...om.com/cgi-bin/prnh/20081117/FSLOGO ) , Med...services is a,relatively novel concept in most su...
(Date:12/2/2008)...athon Health, a leading provider of onsite health ...hat New Balance, the athletic products company, ha...nd manage onsite health clinics and to provide hea...in Maine , Burlington, VT...ading provider of onsite employee health services ...
(Date:12/2/2008)... many families, the problem with the holidays is f...ight into how caregivers of aging parents can brin...experience. , San Mateo, ...he stress of the holiday season is family, especia...xpert Esther Koch , founder of Encore Management...
(Date:12/2/2008)...ional Non-profit Launches Age-related Macular Dege...ost to Eligible Patients and Free Eye-Healthy Cook... (Vocus) December 2, 2008 -- "Do You See What...isease known as Age-related Macular Degeneration (... ,Picture this…. a large black hole in the ...
Breaking Medicine News(10 mins):Health News:The Future of Financing Health Services in Africa 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3
...ewed journal of American Cancer Society) reveals t...t clinically significant screening// criteria for ...uding major depression and post-traumatic stress d...ally all of the women admitted have been experienc...
...hat has FDA approval for treating rheumatoid arthr...ith juvenile rheumatoid// arthritis, according to ...ge of Rheumatology Annual Scientific Meeting in Wa...adalimumab, currently used to treat adults with mo...
...detect synacthen, which when injected simulates th...steroid. This is// most common in sports where spo...-enhancing tool. Synacthen and injecting performan... other than medical treatment is banned. Though ...
...und that pregnant women with systemic lupus are at...ions compared to normal// pregnant women. The stu...ted nationwide covering more than 18 million women...n with systemic lupus should be considered a high-...
Other Medicine News:Health News:Breast Cancer Patients Suffer From Psychological Problems 2Health News:Adalimumab Proves Effective for Children with Juvenile Rheumatoid Arthritis 2Health News:Sports Cheats Beware - New Test To Detect Synacthen Found 2Health News:Pregnant Women With Lupus Are At Greater Risk 2Health News:Pregnant Women With Lupus Are At Greater Risk 3
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists.
...fety Knife with BD Xstar Blade includes a speciall...tects the blade in prodedure and handling. The Xs...ess for manufacturing surgical blades. This propr...nsistency. The arch style, single-bevel geometry ...
Electric high speed system.
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm.
Medicine Products: